@article{65b668e6f5dd4cf3a8671a8a1f36ff0c,
title = "Impact of Malnutrition Using Geriatric Nutritional Risk Index in Heart Failure With Preserved Ejection Fraction",
abstract = "Objectives: This study sought to investigate the relationship between malnutrition and adverse cardiovascular (CV) events in heart failure with preserved ejection fraction (HFpEF). Background: Malnutrition is associated with poor prognosis in a wide range of illnesses, however, the prognostic impact of malnutrition in HFpEF patients is not well known. Methods: Baseline malnutrition risk was determined in 1,677 patients with HFpEF enrolled in the Americas regions of the TOPCAT (Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function) trial, according to 3 categories of the geriatric nutritional risk index (GNRI) as previously validated: moderate to severe, GNRI of <92; low, GNRI of 92 to <98; and absence of risk, GNRI of ≥98. The relationships between malnutrition risk and the primary composite outcome of CV events (CV death, heart failure hospitalization, or resuscitated sudden death) and all-cause death were examined. Results: Approximately one-third of patients were at risk for malnutrition (moderate to severe: 11%; low: 25%; and absence of risk: 64%). Over a median of 2.9-years{\textquoteright} follow-up, compared to those with absent risk for malnutrition, moderate to severe risk was associated with significantly increased risk for the primary outcome, CV death and all-cause death (hazard ratio [HR]: 1.34; 95% confidence interval [CI]: 1.02 to 1.76; HR: 2.06; 95% CI: 1.40 to 3.03; and HR: 1.79; 95% CI: 1.33 to 2.42, respectively) after multivariate adjustment for age, sex, history of CV diseases, and laboratory biomarkers. Conclusions: Patients with HFpEF are at an elevated risk for malnutrition, which was associated with an increased risk for CV events in this population.",
keywords = "heart failure with preserved ejection fraction, malnutrition, prognosis",
author = "Masatoshi Minamisawa and Seidelmann, {Sara B.} and Brian Claggett and Hegde, {Sheila M.} and Shah, {Amil M.} and Desai, {Akshay S.} and Lewis, {Eldrin F.} and Shah, {Sanjiv J.} and Sweitzer, {Nancy K.} and Fang, {James C.} and Anand, {Inder S.} and Eileen O'Meara and Rouleau, {Jean Lucien} and Bertram Pitt and Solomon, {Scott D.}",
note = "Funding Information: Supported by U.S. National Institutes of Health/National Heart, Lung, and Blood Institute (NIH/NHLBI) contract HH-SN268200425207C. The content of this article does not necessarily represent the views of the National Heart, Lung, and Blood Institute or of the Department of Health and Human Services. Dr. Minamisawa received support from the Japanese Circulation Society, the Japanese Society of Echocardiography, and the Uehara Memorial Foundation Overseas Research Fellowship. Dr. Shah has received personal fees from Philips Ultrasound and Bellerophon Therapeutics; and has received research support from Novartis. Dr. Desai is a consultant for Novartis, Abbott, AstraZeneca, Boston Scientific, Boehringer Ingelheim, Regeneron, Relypsa, Corvidia, and Zogenix. Dr. Pitt is a consultant for Bayer and AstraZeneca. Dr. Solomon has received research grants from Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, Bristol-Myers Squibb, Celladon, Cytokinetics, Eidos, Gilead, GlaxoSmithKline, Ionis, Lone Star Heart, Mesoblast, MyoKardia, NIH/NHLBI, Novartis, Sanofi, Pasteur, and Theracos; and is a consultant for Akros, Alnylam, Amgen, AstraZeneca, Bayer, Bristol-Myers Squibb, Cardior, Corvia, Cytokinetics, Gilead, GlaxoSmithKline, Ironwood, Merck, Myokardia, Novartis, Roche, Takeda, Theracos, Quantum Genetics, Cardurion, AoBiome, Janssen, Cardiac Dimensions, and Tenaya. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. Publisher Copyright: {\textcopyright} 2019 American College of Cardiology Foundation",
year = "2019",
month = aug,
doi = "10.1016/j.jchf.2019.04.020",
language = "English (US)",
volume = "7",
pages = "664--675",
journal = "JACC: Heart Failure",
issn = "2213-1779",
publisher = "Elsevier BV",
number = "8",
}